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A B S T R A C T
Patients who are already diagnosed with cutaneous melanoma are at increased risk of developing another primary
melanoma. The occurrence of multiple primary melanoma is a rare phenomenon, varying in frequency, with an esti-
mated incidence ranging from 0.2% to 8.6%. The authors are presenting data on the patients with multiple primary mel-
anoma from the Croatian Referral Melanoma Centre. The clinical, histological and epidemiological characteristics of 36
(3.6%) patients, identified from 991 patients with histologically confirmed melanoma, are analyzed in this study.
Twenty-eight of the patients (78%) had two primary melanomas, six had three melanomas (16,7%) and two (5,6%) had
four melanomas. Diagnosis was established synchronously in 11 patients (30%) and, in the rest of the patients, time in-
terval between the diagnosis of the first and second melanoma varied from 1 month to the longest interval of 16 years.
However, the majority of subsequent melanomas were removed within 2 years of the initial operation. The mean Bres-
low’s thickness of the first melanoma was significantly higher than the mean Breslow’s thickness of the second primary
melanoma. The proportion of in situ to invasive melanomas was greater for the second melanomas compared with the
first melanomas. Therefore, we emphasize the importance of regular follow-up as well as the education in regular self-
-skin examinations in melanoma patients in order to detect subsequent primary melanomas in the early phase.
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Introduction
Epidemiological data indicate that the incidence of
melanoma, one of the most aggressive tumours in hu-
mans is in constant rise throughout the world1. The inci-
dence of melanoma increases with age, and it mostly oc-
curs between 30–70 years of age. Melanoma is also one of
the most common malignant tumours in young adults2.
The major risk factors for the development of melanoma
include excessive sun exposure, number of melanocytic
nevi, cutaneous phenotype, and family and personal his-
tory of melanoma. UV radiation from sunlight appears to
be the principle environmental factor responsible for
melanoma development3–6. It is well known that patients
who have had one cutaneous melanoma are at increased
risk of developing a second primary melanoma7. How-
ever, the appearance of multiple primary melanomas
(MPM) in the same patient is not commonly seen in ev-
eryday dermatological practice. It has been estimated
that the occurrence of MPM ranges from 0.2% to 8.6%8.
Patients and Methods
Data on melanoma patients diagnosed with MPM and
registered at the Croatian Referral Melanoma Centre in
the period 2002–2008 were retrospectively analyzed ac-
cording to the patients’ medical records. Statistical anal-
ysis was conducted using SPSS, version 12. Descriptives
and Pearson’s correlation coefficient were calculated. Ev-
ery patient diagnosed with melanoma and registered at
the Croatian Referral Melanoma Centre is informed
about the disease in details and educated how to preform
regular self-examination of the skin. Special attention is
given to the recognition of the »A, B, C, D« rules in the
assessment of pigment skin lesions.
Results
During the 7-year period (2002–2008) there were 991
newly registered patients diagnosed with melanoma, in-
cluding melanoma in situ, in the Croatian Referral Mela-
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noma Centre. Continuous rise in the number of newly
registered melanoma patients was recorded each year,
starting with 60 patients in 2002 up to 243 melanoma pa-
tients in the year 2008 (Table 1). Out of 991 melanoma
patients, 36 patients (3.6%) were diagnosed with MPM;
28 patients (78%) had 2 primary melanomas, six patients
(16,7%) had 3 melanomas, and two patients (5,6%) had 4
melanomas. There were 17 female (47%) and 19 male
(53%) patients with MPM. The age at the diagnosis of the
first melanoma ranged from 19 to 78 years, with the
mean value of 53,6 years.
Time interval between the removal of the first and
subsequent melanoma ranged from 1 month (more than
30 days) to 16 years, with the average time interval of 41
months. However, most of the subsequent melanomas
(N=19; 52%) were diagnosed within 2 years from the di-
agnosis of the first melanoma. Simultaneous diagnosis of
MPM (multiple tumours diagnosed within 30 days of
each other) was established in 11 patients (30%).
Distribution according to tumour localization of the
second melanoma on the body was similar to that of the
first tumour. Melanomas occurred most commonly on
trunk (namely the posterior part), followed by the lower
extremities and other sites (Figure 1).
As it is shown in the Figure 2, the level of tumour in-
vasion (Clark level) was significantly decreased in the
group of subsequently diagnosed melanomas. Generally,
more of the initial primary melanomas were Clark levels
III and IV, whereas more of the second melanomas were
Clark levels I and II. The proportion of in situ (Clark
level I) to invasive melanomas was greater for the second
melanomas compared with the first melanomas (Figure
2). The mean Breslow thickness of the first melanoma
was 3,1 mm, but the second melanoma was significantly
thinner at 1.3 mm.
The most common hystological type of melanoma was
superficial spreading melanoma. However, in the group
of second melanomas, there were less nodular melano-
mas and more lentigo maligna melanomas diagnosed,
compared with the first melanomas (Figure 3).
Six of our patients (17%) with MPM developed me-
tastases, however, there was no statistically significant
correlation between the number of primary melanomas
and the risk of developing metastatic disease (r= –0,091).
Data regarding the occurence of dysplastic nevi and
family history of melanoma was available for 30 out of 36
of our MPM patients. Presence or history of dysplastic
nevi was determined in 20 (67%) and family history of
melanoma was positive in only 5 (17%) patients. All of
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TABLE 1
NUMBER OF MELANOMA PATIENTS REGISTERED IN THE CROATIAN REFERRAL CENTRE (2002.–2008.)
Year of registration 2002. 2003. 2004. 2005. 2006. 2007. 2008.
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Fig. 3. Distribution of the first and subsequent melanomas by
histologic type of tumour
the patients with positive family history of melanoma
also had dysplastic nevi.
Discussion
The first description of the patient with multiple
MPM was reported in 1952, by Pack et al9. The occur-
rence of MPM is a well-known, but uncommon phenome-
non, with an estimated incidence ranging from 0.2% to
8.6%8. The incidence of MPM in our study, which was
3,6%, correlates with the incidence reported in previuos
series10. Studies report different data of the sex ratio in
MPM patients10–12, however in our population there was
a slight female preponderance noted. Most of the pa-
tients (63–88%) with MPM have two primary tumo-
urs8,9,11,13,14, as it was the case in our study. Interestingly,
a patient with as many as 48 primary melanomas has
been described in the literature15.
Risk of the second primary melanoma in a patient
with a prior melanoma is significantly higher than the
risk of an initial melanoma in an individual from the gen-
eral population. Moreover, patients with a prior mela-
noma have 10–25-fold higher incidence rate of develop-
ing second melanoma compared with the general po-
pulation16,17.
Besides the personal history of prior melanoma, risk
factors for the development of MPM include positive
family history of melanoma (family melanoma meaning
first-degree relative diagnosed with melanoma) and the
presence of dysplastic nevi7. In a study conducted by Ti-
tus-Ernstoff et al18 the presence of 3 or more dysplastic
nevi compared with none was associated with more than
a 4-fold risk of MPM. In a prospective study conducted by
Ferrone et al8, in which 4484 melanoma patients were
analyzed, the estimated cumulative 5-year risk of the
second primary melanoma for the entire cohort was
11.4%, whereas this risk was much higher (at 19,1% and
23,7% respectively) for the patients with a positive family
history or dysplastic nevi8. Among patients with MPM,
38–46% are reported to have a presence or a history of
dysplastic nevi16,19, and 18–38% of MPM patients are re-
ported to have a positive family history of melanoma12,19.
Generally, 6–12% melanomas are family cases, and ap-
proximately 12% of melanoma patients with family his-
tory of melanoma are diagnosed with MPM20. Patients
with numerous dysplastic nevi and positive family his-
tory of melanoma are at the highest risk of melanoma. In
these patients, melanoma is usually diagnosed 10 years
earlier than in general population and are at higher risk
of developing MPM20. However, it is important to empha-
size that to date, the clinical phenotypes of increased
number of atypical nevi and nevi body distribution are
considered to be independent risk factors for melanoma
risk, regardless of family history21. The familial mela-
noma syndromes are associated with germline mutations
in three highly penetrant gene products: p16, alternate
reading frame, and cyclin-dependent kinase 4 (CDK-4)21.
Certain variants in a low-penetrance gene, MC1R, the
melanocortin 1 receptor gene, increase melanoma risk to
a lesser extent and act as a genetic modifier when co-
segregating with a deleterious p16 gene. The penetrance
of these melanoma-predisposing genes is largely influn-
ced by ultraviolet exposure across geographic latitude21,22.
Most second melanomas in this study were detected
within two years of the first, and in one third of cases
multiple melanomas were diagnosed simultaneously. In
various studies, synchronous lesion were found in
20–40% of MPM patients8,10. It has also been reported
that synchronous lesions appear more often in older
patients10. The longest interval between the diagnoses of
the first and subsequent melanoma in our study was 16
years. These data are in concordance with the those from
the literature where in several series the highest risk for
a second melanoma was reported during the first 5 years,
but a much longer time interval of 31 years is possi-
ble10,11,14. Therefore, continued medical follow-up with
complete skin examinations seems prudent, but it is very
important to promote self-skin evaluation in patients to
detect not only metastases but also subsequent primary
melanomas in their earliest phase10.
The melanoma thickness is considered to be one of
the most important independent melanoma prognostic
factors. Therefore, it is important to emphasize that, like
in the majority of other studies7,8,10, our data also con-
firmed that second primary melanoma is significantly
thinner than the first one. Also, in our MPM patients the
proportion of in situ (Clark level I) to invasive melano-
mas was greater for the second melanomas compared
with the first melanomas, confirming the trend toward
thinner subsequent melanomas. Most probably, this is
due to patients’ education and regular and thorough clin-
ical follow up.
Superficial spreading melanoma (SSM) is the most
common type of melanoma which represents 60–70% of
all melanomas23. Nodular melanoma is the second most
common form of melanoma and often has bad prognosis
because it is frequently diagnosed at a thicker stage,
while lentigo maligna melanoma usually has better prog-
nosis because of it’s very long radial growth phase.
Among our MPM patients, the most common hystolo-
gical type of melanoma was SSM. However, there were
less nodular melanomas and more lentigo maligna mela-
nomas diagnosed in the group of second melanomas,
compared with the group of first melanomas (Figure 3).
Burden et al7 carried out a case comparison study of
mortality from melanoma in which each patient with
multiple melanoma was randomly matched with a pa-
tient with a single melanoma in terms of age, sex, Bre-
slow thickness, and body site. The apparent survival ad-
vantage in those with multiple melanoma was not signifi-
cant when the two groups were analysed as two inde-
pendent samples7. On the other hand, Ferrone et al8 re-
ported 5,6% of patients with MPM who died from
melanoma, compared with 15,8% of patients who had a
single melanoma diagnosed and died from it. They specu-
late that, besides the trend towards the thinner subse-
quent melanomas, less agressive disease biology in the
MPM patients may play a role8. In our study, higher
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number of primary tumours in patients with MPM did
not indicate greater risk of developing metastases.
Conclusion
The occurrence of MPM is a rare, but well known phe-
nomenon in the field of dermatooncology. Until today,
various studies have shown that patients with a prior
melanoma are at significantly higher risk of developing
second melanoma compared with the general population.
Among other things, our study confirmed that second
melanoma is usually thinner than the first one. There-
fore, it emphasizes the importance of a life-long fol-
low-up as well as the education in regular self-skin exam-
inations for all melanoma patients, and especially for
those with dysplatic nevi and/or positive family history of
melanoma, in order to detect subsequent primary mela-
nomas in the earliest phase.
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VI[ESTRUKI PRIMARNI MELANOMI; EPIDEMIOLO[KI I PROGNOSTI^KI POKAZATELJI;
ANALIZA 36 SLU^AJEVA
S A @ E T A K
Bolesnici kojima je dijagnosticiran melanom ko`e pripadaju u skupinu s pove}anim rizikom za razvoj slijede}eg
primarnog melanoma. Vi{estruki primarni melanomi su rijetka pojava, a u~estalost varira od 0,2 do 8,6%. Autori iznose
podatke o bolesnicima s vi{estrukim primarnim melanomima iz Hrvatskog Referentnog centra za melanom. Opisani su
klini~ki, patohistolo{ki i epidemiolo{ki pokazatelji 36 bolesnika s vi{estrukim primarnim melanomima, a koji su regi-
strirani iz skupine od ukupno 991 bolesnika s dijagnosticiranim melanomom ko`e. U 32 bolesnika dijagnosticirana su 2
primarna melanoma, u 2 bolesnika dijagnosticirana su 3 primarna melanoma, dok su u 2 bolesnika dijagnosticirana 4
primarna melanoma. Vi{estruki primarni melanomi u 11 bolesnika dijagnosticirani su istovremeno, dok je u ostalih
bolesnika dijagnoza slijede}eg primarnog melanoma postavljena u razdoblju od 1 mjesec do 16 godina nakon dijagnoze
prvog primarnog melanoma. Ve}ina kasnije otkrivenih primarnih melanoma prepoznata je unutar 5 godina od odstra-
njenja prvog primarnog melanoma. Srednja vrijednost debljine melanoma po Breslowu bila je zna~ajno vi{a kod prvih
primarnih u odnosu na slijede}e primarne melanome. Udio melanoma in situ u ukupnom zbroju dijagnosticiranih tu-
mora bio je zna~ajno ve}i u skupini drugih primarnih melanoma. Stoga je iznimno va`no naglasiti potrebu za do`ivot-
nim redovitim kontrolnim dermatolo{ki pregledima, kao i va`nost edukacije bolesnika u redovitim samopregledima
kako bi se {to ve}i broj novonastalih melanoma dijagnosticirao u najranijoj fazi.
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